New facility boosts Kyowa Kirin's biologics capacity
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has opened a new ¥10 billion ($110.8 million) facility in Japan for the production of therapeutic monoclonal antibodies.